IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer CAESAREA, Israel, June 9, 2025 ...
Robust IP portfolio becomes increasingly strategic as global interest in IceCure's platform and next-generation cryoablation technologies grows following ProSense®'s recent FDA marketing authorization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback